ASH Annual Meeting and Exposition
ASH Annual Meeting and Exposition
April 09, 2014
1 min read

HemOnc Today Melanoma and Cutaneous Malignancies to highlight advances in research, patient care

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

The HemOnc Today and team will present live coverage from the HemOnc Today Melanoma and Cutaneous Malignancies annual meeting, starting April 11.

The conference will highlight new research and advances in oncology, dermatology and cutaneous malignancies, including discussions of immunotherapy with ipilimumab, anti-P1 antibodies, targeted therapy for patients with BRAF mutations, combination therapies of BRAF and a MEK inhibitor, immunotherapy with IL-2 and injectable therapies.

“Our program is designed for hematologists/oncologists, dermatologists, researchers, physician assistants, nurses and students,” Sanjiv S. Agarwala, MD, chief of hematology/oncology at St. Luke’s Hospital in Bethlehem, Pa., and a HemOnc Today Editorial Board member said. “This is a dynamic meeting that encourages audience participation, so that we may all benefit from each others’ experiences and challenges. This intimate and interactive approach is our niche — time and space constraints at larger meetings won’t allow for such open communication between faculty and attendees about this specialized topic.”

Sanjiv S. Agarwala, MD 

Sanjiv S. Agarwala

In this year’s agenda, attendees will review the latest information on the diagnosis, management and treatment of melanoma and other cutaneous malignancies presented by a panel of 25 leading experts who will illustrate what implications these updates have for the future. Attendees will also review:

  • Comprehensive education from the biology of the disease to the management of patients, including disease prevention, current and emerging diagnostic technologies, genetic testing, adjuvant therapy, emerging therapies for regional disease and systemic therapies.
  • New research and science covering the MSLT-1 clinical trial results presented by Charles M. Balch, MD, opposing results of T-VEC and Allovectin 7 trials, what’s new in other cutaneous malignancies and coping with the rising costs of melanoma care in 2014.
  • Expert perspective from renowned specialists who have advanced expertise in oncology, dermatology and cutaneous malignancies and will explain how you can apply the new research and advances presented to your own patients and practice.
  • Interactive format offering the opportunity to exchange experiences, ideas and research with faculty and colleagues.
  • Valuable CME to keep your practice current as you earn up to 13 AMA PRA Category 1 Credit(s)™.

Our team will be onsite in New York City throughout the meeting. will feature the meeting’s latest news and developments, videos and physician perspectives.